The use of immune checkpoint inhibitors, particularly antiprogrammed death 1 (PD1)/PD‐ligand 1 (PD‐L1) agents, has markedly improved disease control in NSCLC, which represents about 90% of all lung cancer cases.90 The gene discussed is CD274; the disease is non-small cell lung carcinoma.